WuXi Biologics granted UK GMP certification for two manufacturing facilities in Wuxi

Viking Therapeutics publishes Phase 2 data showing up to 14.7% weight loss with VK2735

NewcelX reports positive biomaterial study results supporting stem cell islet delivery without immune suppression

Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer

Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes

Futura Medical reports statistically significant female sexual function gains in WSD4000 study

GRIN Therapeutics doses first patient in global Phase 3 trial of investigational radiprodil for GRIN-NDD

Phanes Therapeutics reports clinical data on spevatamig chemotherapy combination in frontline treatment of mPDAC

Clover Biopharmaceuticals enrols first participants in Phase 2 trial of respiratory combination vaccine candidates

FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz

Acousia Therapeutics completes patient enrolment in Phase 2 trial of Bimokalner

ZYUS Life Sciences reports positive preliminary results from Phase 2a trial of Trichomylin softgel

Antin to acquire clinical trial equipment provider Emsere

Foresee licenses global rights to MMP-12 inhibitor programmes to Primevera

Arbele's ARB1002 receives US FDA Orphan Drug Designation